FRTX · Fresh Tracks Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $7.94M | $53.0K | $9.0K | - | $486.0K | $4.32M | $92.0K | - | $132.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $627.0K | $609.0K | $1.94M | - | $3.56M | $1.86M | $6.01M | - | $10.22M |
| SG&A | - | $5.32M | $1.81M | $2.41M | - | $3.00M | $3.91M | $3.49M | - | $3.27M |
| Total Operating Expenses | - | $5.95M | $2.42M | $4.35M | - | $6.56M | $5.77M | $9.50M | - | $13.49M |
| D&A | - | - | - | $10.0K | - | - | - | $7.0K | - | - |
| Operating Income | - | $2.00M | ($2.36M) | ($4.34M) | - | ($6.08M) | ($1.46M) | ($9.41M) | - | ($13.36M) |
| Interest Expense | - | $0 | $2.0K | $3.0K | - | $0 | $2.0K | $4.0K | - | $1.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | $2.10M | ($2.28M) | ($4.28M) | - | ($6.02M) | ($1.15M) | ($9.41M) | - | ($13.25M) |
| EPS - Basic | - | $0.32 | ($0.39) | ($1.14) | - | ($2.07) | ($0.01) | ($0.15) | - | ($0.16) |
| EPS - Diluted | - | $0.32 | ($0.39) | ($1.14) | - | ($2.07) | ($0.01) | ($0.08) | - | ($0.15) |
Balance Sheet
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.87M | $12.02M | $8.95M | $10.76M | $8.68M | $11.25M | $14.48M | $17.29M | $26.88M | $21.38M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $406.0K | $609.0K | $256.0K | $635.0K | $571.0K | $1.44M | $1.26M | $2.98M | $1.60M | $1.34M |
| Current Assets | $11.55M | $13.01M | $9.71M | $11.81M | $10.08M | $14.27M | $18.25M | $20.69M | $29.60M | $24.05M |
| Total Assets | $11.59M | $13.06M | $9.84M | $11.97M | $10.27M | $14.45M | $18.51M | $20.79M | $29.72M | $24.19M |
| Current Liabilities | $1.66M | $2.11M | $1.85M | $2.10M | $3.08M | $3.22M | $2.87M | $4.74M | $4.81M | $4.20M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | $4.81M | $4.22M |
| Stockholders' Equity | $9.93M | $10.95M | $7.99M | $9.87M | $7.19M | $11.22M | $15.64M | $16.05M | $24.91M | $19.97M |
| Retained Earnings | ($172.16M) | ($170.93M) | ($173.03M) | ($170.75M) | ($166.47M) | ($161.94M) | ($155.92M) | ($154.78M) | ($145.37M) | ($139.30M) |
Cash Flow
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($4.49M) | - | - | - | ($9.54M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | $0 | - | - |
| Financing Cash Flow | - | - | - | $6.57M | - | - | - | ($55.0K) | - | - |
| CapEx | - | - | - | - | - | - | - | $0 | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | ($9.54M) | - | - |
Ratios
| Metric | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | 25.1% | -4460.4% | -48233.3% | - | -1250.2% | -33.8% | -10225.0% | - | -10120.5% |
| EBITDA margin | - | - | - | -48122.2% | - | - | - | -10217.4% | - | - |
| Net margin | - | 26.5% | -4309.4% | -47511.1% | - | -1238.3% | -26.6% | -10228.3% | - | -10040.2% |
| Free cash flow margin | - | - | - | - | - | - | - | -10369.6% | - | - |
| FCF / Net income | - | - | - | - | - | - | - | 1.01 | - | - |
| R&D / Revenue | - | 7.9% | 1149.1% | 21511.1% | - | 732.5% | 43.2% | 6535.9% | - | 7743.9% |
| SG&A / Revenue | - | 67.0% | 3411.3% | 26822.2% | - | 617.7% | 90.6% | 3789.1% | - | 2476.5% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | 16.1% | -23.2% | -35.7% | - | -41.7% | -6.2% | -45.3% | - | -54.8% |
| Return on equity | - | 19.2% | -28.6% | -43.3% | - | -53.6% | -7.3% | -58.6% | - | -66.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.98 | 6.17 | 5.25 | 5.62 | 3.28 | 4.43 | 6.36 | 4.36 | 6.15 | 5.72 |
| Quick ratio | 6.98 | 6.17 | 5.25 | 5.62 | 3.28 | 4.43 | 6.36 | 4.36 | 6.15 | 5.72 |
| Cash ratio | 6.56 | 5.70 | 4.84 | 5.12 | 2.82 | 3.49 | 5.05 | 3.65 | 5.59 | 5.09 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -1182.0x | -1447.0x | - | - | -729.0x | -2351.8x | - | -13359.0x |
| Equity multiplier | 1.17 | 1.19 | 1.23 | 1.21 | 1.43 | 1.29 | 1.18 | 1.30 | 1.19 | 1.21 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | 0.16 | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.61 | 0.01 | 0.00 | - | 0.03 | 0.23 | 0.00 | - | 0.01 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 1534.6% | -98.8% | -90.2% | - | 268.2% | 2757.6% | 441.2% | - | -7.0% |
| Revenue CAGR (3y) | - | 282.5% | -55.6% | -79.5% | - | -25.7% | - | -49.3% | - | 41.1% |
| Revenue CAGR (5y) | - | 179.0% | -40.9% | -58.3% | - | -31.6% | 4.8% | -50.8% | - | -45.1% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | -62.1% | 53.9% | - | 54.5% | 87.4% | -4.5% | - | -207.1% |
| Net income growth (YoY) | - | - | -99.1% | 54.6% | - | 54.6% | 89.7% | -4.5% | - | -206.4% |
| EPS growth (YoY) | - | - | -3800.0% | -1325.0% | - | -1280.0% | 93.8% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | -60.8% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 38.0% | -2.4% | -48.9% | -38.5% | -71.1% | -43.8% | -30.0% | -44.9% | -8.2% | 6.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$16.01M totalProduct And Service Other$8.01M · 50.0%
Buyout Of Post Closing Obligations$7.94M · 49.6%
Sublicense Income$53.0K · 0.3%
Consulting Services$9.0K · 0.1%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Fresh Tracks Therapeutics against the 5 most active filers in the same SIC group.